The Vaccine They Politicized

On June 8, 2006, the FDA licensed Gardasil, Merck's quadrivalent HPV vaccine, for females aged nine to twenty-six. It targets HPV types 16 and 18 — which cause somewhere around seventy percent of cervical cancers — along with types 6 and 11, responsible for most genital warts. Three weeks later, on June 29, the CDC's Advisory Committee on Immunization Practices voted to recommend it routinely for girls aged eleven and twelve.

Sit with that for a second, because we skipped past it and never came back. A species that had spent all of recorded history watching cancer arrive as weather had just manufactured an object that stops one. Not detects it earlier. Not treats it better. Prevents it, at the causal root, before the first cell goes wrong. Three shots, about three hundred and sixty dollars, and a disease that kills a quarter of a million women a year worldwide stops starting.

We had a few weeks of that before the argument turned into something else entirely.

I'm writing this from further down the road than the dateline suggests, so I already know how it goes, which is the only reason it's worth telling. In the summer of 2006 the fight in American statehouses was not about efficacy, dosing, adjuvants, or duration of protection. It was about what the shot meant. Vaccinating an eleven-year-old against a sexually transmitted infection was read — loudly, in legislative hearings — as an official statement about eleven-year-olds and sex. Parents' rights groups mobilized against mandates. The vaccine was reframed, in a matter of weeks, from an oncology product into a position paper on adolescent morality.

And here is the cruel mechanical detail underneath all of it: the vaccine only works before exposure. That is not a marketing choice; it is immunology. Prophylactic means prophylactic. Which is precisely why the recommended age was eleven — early enough to be reliably ahead of the virus. The biology forced the schedule, and the schedule forced the story. The single feature that made the thing effective was the single feature that made it unacceptable. You cannot separate them. There was no version of this vaccine that arrived without a controversy attached, because the controversy is a direct consequence of the mechanism working.

Then both sides went ahead and confirmed each other's worst reading.

In February 2007 Texas governor Rick Perry issued an executive order mandating Gardasil for sixth-grade girls, explicitly bypassing a legislature he knew would refuse. Merck, it emerged, had been bankrolling a nationwide state-mandate push, routing money through a legislators' advocacy group called Women in Government, and one of its three Texas lobbyists was Perry's former chief of staff. The company suspended the campaign under scrutiny. The Texas legislature overturned the order within months.

So the people who said this is being pushed on us by interests that don't have our children's health at heart turned out to be describing something real.

The causality is worth getting right, though, because the tempting version is wrong. The opposition did not need the scandal. Parents' rights groups were mobilizing in the summer of 2006; Perry's order and the Women in Government revelations came the following February. The objections predate the lobbying story by half a year. Merck's money didn't create the resistance — it confirmed it, which is worse in its way, because a suspicion that gets confirmed stops being a suspicion and becomes a fact people are entitled to. A true criticism of the distribution got laundered into a false criticism of the thing.

And underneath that sits the structural version, which I think is the real one. A single for-profit monopoly holding a cancer prevention, quietly financing a campaign to make its own product compulsory, is not an arrangement in which good-faith public trust is available. That isn't a messaging failure, and no amount of better communication would have fixed it, because the arrangement itself is the problem. A commons good routed through a private toll booth manufactures its own opposition — and then the opposition gets blamed on the public's superstitions.

Meanwhile the thing kept being what it was.

In January 2024, researchers led by Tim Palmer published population-level data from Scotland in the Journal of the National Cancer Institute. Scotland ran its program on the bivalent vaccine, Cervarix — a different product from Gardasil, aimed at the same two oncogenic types, 16 and 18 — and delivered it a different way, which turns out to be the part that matters. Among women born between 1988 and mid-1996 who were vaccinated at ages twelve to thirteen, they found zero cases of invasive cervical cancer, at any dose count, through follow-up ending in 2020. None. Not a reduced rate — an empty column.

But the sentence that should have ended the American argument isn't in that paper's headline. It's in its methods.

Scotland ran two programs at once. The routine cohort got the shot at twelve or thirteen, in school, from a nurse, as the default — uptake above eighty percent. The catch-up cohort were girls already too old for the school session, reached instead through general practice and community clinics; among the oldest of them, the ones who had left school entirely, uptake ran around forty percent.

Same country. Same year. Same vaccine. Same culture, the same parents, an identical distribution of feelings about twelve-year-olds and sex. The only variable that moved was how the vaccine got to the arm. Above eighty percent when it came to them. Around forty when they had to go to it.

Nobody in Scotland won the meaning fight. They routed around it.

Which forces a correction on the sentence I most wanted to write. Access follows meaning, not function is close, and it is wrong in the most interesting available way. Meaning matters exactly as much as the delivery architecture lets it matter. Route a vaccine through fifty statehouse debates about adolescent morality and meaning becomes decisive — it is the only variable in the room. Route it through the school calendar and meaning becomes a form most people never get around to filling out.

Honesty requires the American number here, because it is not zero and pretending otherwise cedes the argument to anyone holding a chart. The ACIP recommendation held. HPV vaccine went onto the childhood schedule. US coverage now sits near sixty-three percent up-to-date among thirteen-to-seventeen-year-olds, with about seventy-eight percent having had at least one dose, and it has been roughly flat for three years. What failed in 2007 was the mandate, not the vaccine. But sixty-three percent is remarkably close to Scotland's catch-up figure and nowhere near its routine one. We built school-leaver delivery for a school-aged intervention, and then spent two decades arguing about why people weren't showing up.

America did not lose because it was more prudish than Scotland. It lost because it chose a delivery path that made prudishness load-bearing.

The function of that syringe was settled in a laboratory in about three years. Its delivery was never really designed at all — it was left to whatever each state's politics happened to produce. We built the hard part fast and then never got around to the easy part, and the difference between those two timelines is counted in women.

The strangest part, the part I keep returning to, is that none of the argument reached the virus. HPV did not adjust its transmission strategy in response to Texas House Bill 1098. It has no receptors for cultural anxiety. It went on being a small unfeeling ring of DNA in a shell, doing the only thing it does, indifferent to the meaning we assigned to the machine that stops it.

There is a box in a refrigerator somewhere. It has been sitting there since 2006 being quietly, boringly correct, waiting for us to finish deciding what it's about.

It'll wait. It's the only one of us that isn't in a hurry.